New dementia sits at the center of this dementia and brain health question.

Recent research from UC San Diego offers compelling evidence that women may benefit from knowing their dementia risk decades before symptoms appear. A study published in March 2026 in JAMA Network Open found that a simple blood test measuring phosphorylated tau 217 (p-tau217)—a protein linked to brain changes in Alzheimer’s disease—can predict dementia risk up to 25 years before cognitive decline becomes noticeable. This discovery has significant implications for women’s health planning and preventive care strategies.

However, the current evidence doesn’t yet support routine screening in younger, asymptomatic women. The research was conducted on women aged 65-79 who were followed for up to 25 years after their baseline blood draw in the 1990s. While the 25-year prediction window is remarkable, healthcare providers and researchers emphasize that additional studies are needed before the test becomes standard clinical practice for early identification and prevention. This article explores what the research shows, who might benefit, and what the next steps in dementia prevention look like for women.

What Does the New Dementia Blood Test Measure and How Does It Work?
Which Women Face Higher Dementia Risk According to the Research?
What Did the Actual Research Study Include and How Long Did Researchers Follow Women?
Should Women Under 50 Get This Blood Test Now?
What Are the Limitations and Uncertainties About This Blood Test?
What Preventive Strategies Make Sense for Women Concerned About Dementia Risk?
What’s Next for Dementia Blood Testing and Prevention Research?
Conclusion

What Does the New Dementia Blood Test Measure and How Does It Work?

The blood test identifies phosphorylated tau 217 (p-tau217), a protein fragment that accumulates in the brain during the development of Alzheimer’s disease and related dementias. Unlike older diagnostic methods that require invasive brain imaging or spinal fluid collection through lumbar puncture, this test is significantly less invasive—a simple blood draw is all that’s needed. The p-tau217 biomarker reflects actual changes happening in the brain tissue, making it a direct biological marker rather than an indirect measure of cognitive function. The UC San Diego study demonstrated that p-tau217 levels don’t randomly predict dementia risk equally across all groups.

Higher biomarker concentrations correlated with increased dementia risk in a dose-response pattern: women with progressively higher p-tau217 levels showed progressively higher disease risk over the 25-year follow-up period. This isn’t a pass-or-fail test but rather a risk stratification tool that could theoretically help identify women on a pathway toward cognitive decline while they still have years to implement preventive strategies. The advantage over existing methods is clear: spinal fluid biomarker tests require hospitalization and carry small but real risks of complications like headaches or infection. Brain imaging with PET scans or advanced MRI is expensive, requires specialized equipment, and exposes patients to radiation. A blood test addresses all these limitations while providing valid biological information about brain pathology.

What Does the New Dementia Blood Test Measure and How Does It Work?

Which Women Face Higher Dementia Risk According to the Research?

The UC San Diego research identified two critical factors that modify dementia risk in women: age at baseline and genetic predisposition. The association between p-tau217 levels and dementia was significantly stronger in women over age 70 than in women under 70 at the study’s starting point. This suggests that while the test may predict risk across a broad age range, it may be more informative and clinically relevant for older women who are closer to the typical age of symptom onset. Genetic background substantially influences risk as well.

Women who carry the APOE ε4 genetic variant—a well-established risk factor for Alzheimer’s disease—showed higher dementia risk when combined with elevated p-tau217 levels. A woman without this genetic variant but with high p-tau217 may have a lower risk trajectory than a woman with both the genetic risk factor and high biomarker levels. However, one important caveat: carrying APOE ε4 or having high p-tau217 doesn’t mean dementia is inevitable. Many women in the study with these risk factors remained cognitively healthy throughout the follow-up period.

What Did the Actual Research Study Include and How Long Did Researchers Follow Women?

The UC San Diego study was not a small preliminary trial. Researchers analyzed data from 2,766 women aged 65-79 who participated in the Women’s Health Initiative Memory Study, a long-term research project that began in the 1990s. All participants were cognitively healthy when they enrolled—no one had dementia or cognitive impairment at the study’s start. Researchers then tracked these women’s cognitive health for up to 25 years, during which time some developed dementia and others remained cognitively normal.

This longitudinal design is what gives the 25-year prediction claim its credibility. The blood test wasn’t given retroactively or in isolation; it was measured when women were in their 60s and 70s, and researchers then observed who actually developed dementia in the decades that followed. The study size and duration make this stronger evidence than early-stage research, though researchers acknowledge that validation in additional populations is still needed before the test becomes standard clinical practice. The research was published in a high-impact peer-reviewed journal (JAMA Network Open) in March 2026, giving it relatively recent validation but not yet the decades of clinical implementation data that would support universal screening recommendations.

What Did the Actual Research Study Include and How Long Did Researchers Follow Women?

Should Women Under 50 Get This Blood Test Now?

This is where the gap between research findings and current clinical recommendations becomes important. The study’s dramatic “25 years before symptoms” finding might suggest that women in their 40s or even 30s should get tested, but that’s not what the research actually supports. The study participants were 65-79 at baseline, meaning they were already in or beyond early late-life. Extrapolating to 40-year-old women involves assuming that p-tau217 levels at age 40 predict the same risk as p-tau217 at age 65-79, which hasn’t been studied.

Current medical guidance does not recommend routine blood testing for dementia risk in asymptomatic individuals of any age. Researchers studying the biomarker have been explicit about this limitation: additional clinical trials are needed to determine whether early identification of high-risk women actually leads to interventions that prevent or delay dementia. In other words, knowing you’re at risk years early isn’t helpful unless there’s an evidence-based action plan that reduces that risk—and that evidence isn’t yet established. What women in their 40s and 50s can do now is focus on modifiable risk factors: cardiovascular health, cognitive engagement, physical activity, quality sleep, and managing conditions like diabetes and hypertension. These interventions have clear evidence for supporting brain health and may reduce dementia risk independent of biomarker status.

What Are the Limitations and Uncertainties About This Blood Test?

While p-tau217 is a real biological marker of brain changes, the presence of the protein in the blood doesn’t automatically mean someone will develop dementia symptoms. Pathologic changes in the brain don’t always translate to clinical disease. Some women in the UC San Diego study had elevated p-tau217 levels but remained cognitively normal throughout the 25-year follow-up. This means the test identifies risk, not destiny—a crucial distinction that can be emotionally and psychologically important.

Another significant limitation: the test was validated in a specific population (women in the Women’s Health Initiative) who were predominantly older, largely white, and followed by research institutions. Whether the same biomarker thresholds and risk predictions apply to younger women, women of other racial or ethnic backgrounds, or women with different health profiles remains unknown. Validation in diverse populations is part of what researchers consider essential before clinical implementation. Finally, there’s currently no established intervention proven to prevent or slow dementia in people with elevated p-tau217 but no symptoms. Even if a woman discovers she has high biomarker levels, there’s no specific treatment she can start based on that information alone—at least not yet.

What Are the Limitations and Uncertainties About This Blood Test?

What Preventive Strategies Make Sense for Women Concerned About Dementia Risk?

Women who are concerned about dementia risk—whether because of family history, genetic testing results, or simply because they want to be proactive—should focus on interventions with solid evidence. Cardiovascular health is foundational: hypertension, diabetes, high cholesterol, and obesity all increase dementia risk. Managing these conditions reduces risk regardless of biomarker status.

Cognitive and physical activity also matter substantially. Regular aerobic exercise, social engagement, continuing education or mentally stimulating hobbies, and sleep quality have all been associated with better cognitive aging. These aren’t dramatic interventions, but they’re accessible to most women and have benefits beyond dementia prevention, including improved mood, bone health, and cardiovascular fitness.

What’s Next for Dementia Blood Testing and Prevention Research?

The research on p-tau217 and other blood-based biomarkers represents a significant advance in our ability to detect brain changes before symptoms appear. Multiple research groups are now studying whether very early intervention—potentially based on biomarker status alone—can prevent or delay cognitive decline.

These studies will be crucial for determining whether knowing your risk years early actually changes outcomes. The field is also moving toward multi-marker blood tests that measure several different proteins and fragments simultaneously, potentially improving predictive accuracy. As this research evolves, testing recommendations will likely become more refined: for instance, tests might eventually be recommended for certain age groups or for women with specific risk factors (family history, genetic predisposition, or cardiovascular disease) rather than universal screening.

Conclusion

The UC San Diego research demonstrating that blood p-tau217 levels can predict dementia risk up to 25 years before symptoms appear is scientifically significant and represents meaningful progress in early detection. However, current evidence does not support routine testing of asymptomatic women, particularly those under 50. The research was conducted in older women, and additional studies are needed to understand clinical utility—that is, whether early identification leads to interventions that actually prevent or delay dementia.

For women concerned about brain health and dementia prevention, the immediate focus should remain on evidence-based lifestyle modifications: managing cardiovascular risk factors, staying cognitively and physically active, prioritizing quality sleep, and maintaining social connections. As research continues to clarify which biomarkers predict true clinical risk and which interventions prevent decline, screening recommendations will likely evolve. Stay informed through trusted sources like the Alzheimer’s Association and discussions with your healthcare provider about your individual risk profile and the best approach to brain health at your stage of life.